Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with anagrelide

British Journal of Haematology

Volumn 104, Issue 4, 1999, Pages 886-892

  Bellucci, Sylvia ^a   Legrand, C ^b   Boval, B ^a   Drouet, L ^a   Caen, J ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Anagrelide; Essential thrombocythaemia; Platelet function; Platelet glycoprotein IV; Platelet volume

Indexed keywords

ANAGRELIDE; CD36 ANTIGEN;

ADULT; ARTICLE; BLEEDING TIME; CASE REPORT; CELL PROLIFERATION; CHILD; DRUG MECHANISM; HUMAN; LEUKEMOGENESIS; MEGAKARYOPOIESIS; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE VOLUME; THROMBOCYTHEMIA;

EID: 0033003618     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01234.x     Document Type: Article

References (37)

1. Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. American Journal of Medicine, 92, 69-76.
2. Balduini, C.L., Bertolino, G., Noris, P. & Ascari, E. (1992) Effect of Anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica, 77, 40-43.
3. Barbui, T., Finazzi, G., Dupuy, E., Kiladjian, J.J. & Brière. J. (1996) Treatment strategies in essential thrombocythemia: a critical appraisal of various experiences in different centers. Leukemia and Lymphoma. 22, (Suppl. 1), 149-160.
4. Bellucci, S., Harousseau, J.L., Brice, P. & Tobelem, G. (1988) Treatment of essential thrombocythemia by alpha 2a interferon. Lancet, ii, 960-961.
5. Bellucci. S., Ignatova, E., Jaillet, N. & Boffa, M.C. (1993) Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thrombosis and Haemostasis, 70, 736-742.
6. Bellucci, S., Janvier, M., Tobelem, G., Flandrin, G., Charpak, Y., Berger, R. & Boiron, M. (1986) Essential thrombocythemias: clinical evolutionary and biological data. Cancer, 58, 2440-2447.
7. Booth, W.J., Berndt, M.C. & Castaldi, P.A. (1984) An altered platelet granule glycoprotein in patients with essential thrombocythemia. Journal of Clinical Investigation, 73, 291-297.
8. Chistolini, A., Mazzucconi, M.G., Ferrari, A., La Verde, G., Ferrazza, G., Dragoni, F. Vitale, A., Arcieri, R. & Mandelli, F. (1990) Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica, 75, 537-540.
9. Colombi, M., Radaelli, F., Zocchi, L. & Maiolo, A.T. (1991) Thrombotic and hemorrhagic complications in essential thrombocythemia: a retrospective study of 103 patients. Cancer, 67, 2926-2930.
10. Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. & Barbui, T. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal of Medecine, 322, 1132-1136.
11. Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F. & Barbui, T. (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia. Journal of Clinical Oncology, 8, 556-562.
12. Dimitriadou, C., Sultan, Y., Levy-Tolodano, S., Bernal-Hoyos, E. & Caen, J.P. (1974) Etude du temps de saignement quantitatif et des fonctions plaquettaires au cours des purpuras thrombopéniques. Nouvelle Presse Médicale, 3, 1425-1428.
13. Fenaux, P., Simon, M., Caulier, M.T., Lai, J.L., Goudemand, J. & Bauters, F. (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer, 66, 549-556.
14. Finazzi, G., Budde, U. & Michiels, J.J. (1996) Bleeding time and platelet function in essential thrombocythemin and other myeloproliferative syndromes. Leukemia and Lymphoma, 22, (Suppl. 1), 71-78.
15. Gruel, Y., Boizard, B., Daffos, F., Forestier, F., Caen, J. & Wautier, J.L. (1986) Determination of platelet antigens and glycoproteins in the human fetus. Blood, 68, 488-492.
16. Harrison, C.N., Linch, D.C. & Machin, S.T. (1998) Desirability and problems of early diagnosis of essential thrombocythemia. Lancet, 351, 846-847.
17. Hehlmann, R., Jahn, M., Baumann, B. & Köpcke, W. (1988) Essential thrombocythemia: clinical characteristics and course of 61 cases. Cancer, 61, 2487-2496.
18. Kieffer, N., Bettaieb, A., Legrand, C., Coulombel, L., Vainchenker, W., Edelman, L. & Breton-Gorius, J. (1989) Developmentally regulated expression of a 78 kDa erythroblast membrane glycoprotein immunologically related to the platelet thrombospondin receptor. Biochemical Journal, 262, 835-842.
19. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
20. Lahuerta-Palacios. J.J., Bornstein, R., Fernandez-Debora, F.J., Gutierrez-Rivas, E., Ortiz, M.C., Larregla, S., Calandre, L. & Montero-Castillo, J. (1988) Controlled and uncontrolled thrombocytosis: its clinical role in essential thrombocythemia. Cancer, 61, 1207-1212.
21. Lawler, J., Cohen, A.M., Chao, F.C. & Moriarty, D.J. (1987) Thrombospondin in essential thrombocythemia. Blood, 67, 555-558.
22. Legrand, C., Dubernard, V., Kieffer, N. & Nurden, A.T. (1988) Use of a monoclonal antibody to measure the surface expression of thrombospondin following platelet activation. European Journal of Biochemistry. 171, 393-399.
23. Legrand, C., Bellucci, S., Disdier, M., Edelman, L. & Tobelem, G. (1991a) Platelet thrombospondin and glycoprotein IV abnormalities in patients with essential thrombocythemia: effect of alpha-interferon treatment. American Journal of Hematology, 38, 307-313.
24. Legrand, C., Pidard, D., Beiso, P., Tenza, D. & Edelman, L. (1991b) Interaction of a monoclonal antibody to glycoprotein IV (CD36) with human platelets and its effect on platelet function. Platelets, 2, 99-105.
25. Levin, J. & Bessman, D. (1983) The inverse relation between platelet volume and platelet number: abnormalities in hematologic disease and evidence that platelet size does not correlate with platelet age. Journal of Laboratory and Clinical Medicine, 101, 295-307.
26. Mazur, E., Rosmarin, A.G., Sohl, P.A., Newton, J.L. & Narendran, A. (1992) Analysis of the mechanism of Anagrelide-induced thrombocylopenia in humans. Blood, 79, 1931-1937.
27. Mazzucconi, M.G., De Sanctis, V., Chistolini, A., Dragoni, F. & Mandelli, F. (1992) Therapy with Anagrelide in patients affected by essential thrombocythaemia: preliminary results. Haematologica, 77, 315-317.
28. Mielke, C.H. & Kaneshiro, M.M. (1969) The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood, 34, 204-209.
29. Nurden, A.T., Dupuis, D., Kunicki, T.J. & Caen, J.P. (1981) Analysis of the glycoprotein and protein composition of Bernard-Soulier platelets by single and two-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis. Journal of Clinical Investigation, 67, 1431-1440.
30. Sedlacek, S.M., Curtis, J.L., Weintraub, J. & Levin, J. (1986) Essential thrombocythemia and leukemic transformation. Medicine, 65, 353-365.
31. Silverstein, M.N., Petitt, R.M., Solberg, L.A., Jr. Fleming, J.S., Knight, R.C. & Shacter, L.P. (1988) Anagrelide: a new drug for treating throrabocytosis. New England Journal of Medicine, 318, 1292-1294.
32. Silverstein, M.N., Petrone, M.E., Petitt, R.M., Dement. M.P. & Vukovich, R.A. (1996) The safety profile of Anagrelide for treatment of thrombocythemia. Blood, 88, 583a.
33. Solberg, L.A., Jr, Tefferi, A., Oles, K.J., Tarach, J.S., Petitt, R.M., Forstrom, L.A. & Silverstein, M.N. (1997) The effects of Anagrelide on human megakaryocytopoiesis. British Journal of Haematology, 99, 174-180.
34. Sterkers, Y., Preudhomme, C., Laï, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, D., Bauters, F. & Fenaux, P. (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thromhocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood, 91, 616-622.
35. Tandon, N.N., Lipsky, R.H., Burgess, W.H. & Jamieson, G.A. (1989) Isolation and characterization of platelet glycoprotein IV (CD36). Journal of Biological Chemistry, 264, 7570-7575.
36. Thibert, V., Bellucci, S., Cristofari, M., Gluckman, R. & Legrand, C. (1995) Increased platelet CD36 constitutes a common marker in myeloproliferative disorders. British Journal of Haematology, 91, 618-624.
37. Thibert, V., Bellucci, S., Edelman, L., Tandon, N.N. & Legrand, C. (1992) Quantification of platelet glycoprotein IV (CD36) in healthy subjects and in patients with essential thrombocythaemia using an immunocapture assay. Thrombosis and Haemostasis, 68, 600-605.